intelliatx.com (NTLA): Company Short-Term Debt

NTLA (Intellia Corp) - company brandmark

This chart of Intellia Therapeutics (NTLA) stock quotes demonstrates the dynamics of a company developing cutting-edge treatments through genome modification. A team of top scientists is retained via an option system and scientific freedom. The business relies on exclusive patents and alliances with industry behemoths, which precludes price wars. The current metric stands at 0.02, while the budget is replenished by partnership payments until products reach the market.

intelliatx.com (NTLA) - Amount of Current Liabilities from 07/04/2022 to 11/01/2026

Intellia Corp - analytical breakdowns and key metrics (NTLA)

- stock price and consensus target price:
Stock Price Intellia Therapeutics, Inc.|NTLA - Analyst Median Target
- stock exchange capitalization data:
Market Value Intellia Therapeutics, Inc.|NTLA - Business Value
- shareholders' equity book value data:
Accounting Value per Share Intellia Therapeutics|NTLA - Total Net Assets|Market Capitalization to Book Value Ratio intelliatx.com|NTLA - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Intellia Therapeutics|NTLA - Long-Term Debt to Equity|Short-Term Debt to Equity Intellia Therapeutics|NTLA - Company Debts|Debts to Book Capitalization Intellia Therapeutics, Inc.|NTLA - Long-Term Debt Volume|Company Short-Term Debts Intellia Therapeutics|Quick Liquidity Indicator intelliatx.com
- earnings and valuation multiples indicators:
NTLA - Final Profit
Fundamental company valuation:Intellia Therapeutics, Inc. (NTLA)
Mass-produced product of Intellia Therapeutics

Genetic mutation risks and CRISPR regulatory barriers create high financial uncertainty for Intellia Therapeutics (NTLA). Analyzing the history of short-term liabilities, an investor sees the total volume of obligations with a maturity date of up to one year. This metric measures current liquidity, determining the company's ability to service debt without halting expansion. A decrease in this indicator minimizes default risk but may limit development rates. The asset requires cautious monitoring of the balance between borrowing and growth.

Competitors of Intellia Therapeutics

Tempus AI, Inc - Company Short-Term Debts|Short-Term Debt Volume Qiagen NV QGEN|Ionis Pharma (IONS) - Company Short-Term Debt|Company Short-Term Indebtedness RGEN|Company Current Liabilities RNA|CRSP (crisprtx.com) - Amount of Current Liabilities|Company Short-Term Debts WGS|RARE - Short-Term Debt|Company Short-Term Debt Beam Therapeutics Corp BEAM|Sarepta Corp - Company Short-Term Debt|TWST - Company Short-Term Debt|TXG: Company Short-Term Debt|STOK: Company Short-Term Debts|BLFS - Short-Term Debt Volume|WVE (Wave Life Sciences Corp) - Company Short-Term Debts|Company Short-Term Debts Maze Therapeutics Corp|Company Current Liabilities SION (Sionna Therapeutics Inc)|PRME (primemedicine.com) - Company Short-Term Loans and Borrowings|Taysha Gene Therapies, Inc. - Company Current Liabilities|Amount of Current Liabilities QURE (uniQure NV)|MeiraGTx PLC - Company Short-Term Debts|Company Short-Term Loans and Borrowings RGNX (REGENXBIO Corp)|SLDB: Company Short-Term Debts|Short-Term Debt ocugen.com (OCGN)|Company Short-Term Debt PacBio|BNTC: Company Short-Term Loans and Borrowings|Company Short-Term Debts DSGN|Company Short-Term Debts Rocket Corp (RCKT)|Company Short-Term Debt 4D Molecular Therapeutics FDMT|LXEO (Lexeo Therapeutics Inc.) - Current Liabilities|Korro Bio, Inc - Company Short-Term Debts|Short-Term Debt Editas Medicine Inc|SLN (Silence Therapeutics Inc.) - Company Current Liabilities|ProQR Therapeutics (PRQR) - Company Short-Term Debts|Company Current Liabilities CDXS|SGMO (sangamo.com) - Amount of Current Liabilities|Company Short-Term Debts NAUT|Short-Term Debt Volume Metagenomi Inc.|Company Short-Term Debts DTIL (Precision BioSciences)|GBIO - Company Current Liabilities|BOLD - Company Short-Term Debt|Short-Term Debt Volume Exicure, Inc. XCUR|imunon.com (IMNN) - Company Short-Term Debt|Company Short-Term Indebtedness PHIO|Company Current Liabilities MBIO|RNAZ (TransCode) - Amount of Current Liabilities|Company Short-Term Debt Bionano Genomics, Inc. (BNGO)|Company Short-Term Debt APDN (adnas.com)|Company Short-Term Debts BLUE (bluebird bio)|Company Short-Term Debts ImmunoPrecise Antibodies Ltd IPA|Omega - Company Short-Term Debts|OMIC (Singular Genomics Corp) - Company Short-Term Indebtedness|Regulus Therapeutics (RGLS) - Company Short-Term Debt|Company Short-Term Indebtedness SYRS|TBIO (Telesis Bio) - Company Short-Term Debts|Company Short-Term Debts TRACON Pharmaceuticals Inc.|Company Short-Term Debts UBX